03/04/2017 The EORTC 62005 study, recently published in Journal of Clinical Oncology demonstrated that patients with metastatic GIST continue to benefit from imatinib, a targeted therapy, with 13% of patients reported to be alive 10 years from starting treatment. It also confirmed that genomics might help pre...
Does radiofrequency ablation of unresectable colorectal liver metastases prolong long-term... 22/03/2017
GICC 2016 will highlight primary therapy of early GI cancer with a focus on pancreatic and... 27/11/2015
14M Genomics and EORTC and Announce First Results from their Collaboration on Tumour Profi... 13/11/2015